Adaptimmune Therapeutics plc (473A) — Working Capital to Net Assets Ratio
Adaptimmune Therapeutics plc (473A) has a Working Capital to Net Assets ratio of -37.5% as of June 2025. Working capital of €26.60 Million (current assets of €78.11 Million minus current liabilities of €51.51 Million) is measured against net assets of €-70.96 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Adaptimmune Therapeutics plc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Adaptimmune Therapeutics plc Working Capital to Net Assets (2016–2024)
This chart shows how Adaptimmune Therapeutics plc's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at -37.5%, reflecting working capital of €26.60 Million against net assets of €-70.96 Million EUR. See Adaptimmune Therapeutics plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Adaptimmune Therapeutics plc (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Adaptimmune Therapeutics plc from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Adaptimmune Therapeutics plc.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 1043.5% | €123.64 Million | €11.85 Million | €188.17 Million | €64.53 Million | ▲ +702.4 pp |
| 2023 | 341.1% | €134.76 Million | €39.51 Million | €207.55 Million | €72.79 Million | ▲ +107.9 pp |
| 2022 | 233.1% | €190.87 Million | €81.88 Million | €255.37 Million | €64.50 Million | ▲ +61.8 pp |
| 2021 | 171.4% | €352.92 Million | €205.96 Million | €415.46 Million | €62.54 Million | ▲ +66.1 pp |
| 2020 | 105.2% | €359.08 Million | €341.23 Million | €398.15 Million | €39.07 Million | ▲ +35.6 pp |
| 2019 | 69.7% | €86.15 Million | €123.64 Million | €120.49 Million | €34.34 Million | ▼ -14.0 pp |
| 2018 | 83.7% | €206.66 Million | €246.88 Million | €231.09 Million | €24.44 Million | ▲ +6.9 pp |
| 2017 | 76.8% | €155.87 Million | €202.98 Million | €230.18 Million | €74.31 Million | ▼ -18.6 pp |
| 2016 | 95.4% | €158.48 Million | €166.14 Million | €198.75 Million | €40.27 Million | — |